When to Hire a Regulatory Consultant for Your Biotech (Phase 2 is the Sweet Spot)

Introduction

You're leading a small biotech. You've got promising Phase 2 data. Investors are paying attention. And someone on your team just asked: "Should we hire a regulatory consultant?"

The honest answer? You should have hired one six months ago.

But the second-best time is right now.

In this guide, I'll explain exactly when to bring in regulatory expertise, why Phase 2 is the critical window, and how to know if you're already falling behind.

The Short Answer

Hire a regulatory consultant at the end of Phase 2, before you begin planning Phase 3 trials.

At this stage, you still have time to:

Identify regulatory gaps before they become costly problems

Choose the optimal approval pathway (standard vs accelerated)

Build a submission-ready regulatory strategy

Avoid the Phase 3 scramble that sinks 60% of drugs

Wait until Phase 3, and you're playing catch-up. Wait until submission, and you're already in crisis mode.

Why Phase 2 is the Regulatory Sweet Spot

Here's what happens at the end of Phase 2:

What You Have What You Still Need

Initial efficacy data Regulatory strategy for Phase 3 and beyond

Early safety profile Gap analysis against MHRA/EMA/FDA requirements

Development momentum Document templates and submission planning

Investor interest Clear pathway to market approval

This is the moment when regulatory decisions have maximum impact and minimum cost.

Hire too early (Phase 1): You're paying for strategy before you have enough data to inform it.

Hire too late (Phase 3/ submission): You're paying for emergency fixes, expensive rework, and delayed timelines.

Hire at Phase 2: You're paying for prevention. That's always cheaper than cure.

5 Warning Signs You've Already Left It Too Late

Not sure if you've missed the window? Here are the red flags:

1. You're in Phase 3 and no one has reviewed your dossier against MHRA requirements.

If you're already running Phase 3 trials without a regulatory gap analysis, you're flying blind. Critical documents may be missing. Data may be in the wrong format. Pathways may be suboptimal.

2. You're not sure which market to target first (UK, EU, or US).

Post-Brexit, MHRA and EMA requirements are diverging. Choosing the wrong market first can add 12-18 months to your timeline. A regulatory consultant should have helped you answer this at Phase 2.

3. Your team is writing regulatory documents for the first time.

SmPCs, PILs, QOS, Clinical Overviews — these aren't academic papers. They have specific structures, language, and regulatory expectations. If your scientists are learning on the job, mistakes are being baked in.

4. You're six months from submission and have no eCTD publishing plan.

eCTD submissions require specialist software (like Freyr) and deep validation knowledge. First-time submitters almost always face technical rejections without expert help.

5. No one owns the regulatory timeline.

Your CSO owns science. Your CMO owns clinical. Your CFO owns budget. But if no single person is accountable for regulatory milestones, deadlines will slip. Guaranteed.

If any of these sound familiar, you're not alone — but you need to act now.

What a Regulatory Consultant Actually Does for a Phase 2 Biotech

At BioReg Life Sciences, we provide end-to-end regulatory affairs and lifecycle support. Here's what that means for a small biotech:

Service What We Deliver

Regulatory gap analysis A 2-day review of your current position against MHRA/EMA/FDA requirements. You get a clear roadmap of what's missing and what's urgent.

Regulatory strategy Market entry planning, pathway selection (standard vs accelerated), timeline forecasting, and risk assessment.

Document templates Submission-ready M1 and M2 templates with guidance notes. Your scientists fill in the content; we provide the structure.

Document readiness review We review your completed drafts, mark up changes, and ensure regulator-ready quality before publishing.

eCTD publishing Using industry-leading Freyr software, we compile, validate, and publish your full dossier for MHRA, EMA, or FDA submission.

Submission management We submit to the regulator, manage authority queries, and coordinate responses.

Lifecycle maintenance Post-approval, we host your submission sequence in our DMS and manage variations, renewals, and PSURs.

The result? You get your science to market. Faster. Compliantly. Without the headache.

Why BioReg Life Sciences?

We're not a massive CRO where your project becomes a number. We're a UK-based, senior-led regulatory consultancy built for small biotechs.

Our track record:

5,000+ submissions completed

100% acceptance rate across MHRA, EMA, and FDA

40+ years combined regulatory experience (including Cheryl's work on the world's first eCTD submission)

Our promise:

No junior hand-offs. You work directly with senior consultants.

No blagging. We're honest about what we can and can't do.

No hidden fees. Fixed prices where possible, transparent retainers otherwise.

Our location: Nottingham and London, serving UK and global clients.

What Happens When You Hire Us at Phase 2

The free first step: You book a 30-minute regulatory chat. No cost. No obligation. Just honest answers to your questions.

If it makes sense to proceed: You commission our fixed-price Regulatory Health Check (£5000). We review your regulatory position, deliver a top level gap analysis report, and walk you through findings in a strategy call.

From there: We move into full regulatory support — strategy, templates, document review, eCTD publishing, submission, and lifecycle maintenance.

One partner. Every stage. Complete accountability.

Call to Action

If you're in Phase 2 (or wish you had planned better when you were), book a free 30-minute regulatory chat.

No sales pitch. No obligation. Just senior regulatory expertise applied to your specific situation.

Book a meeting today and lets get your science to the market: thomas@bioreglifesciences.com